Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY-CRM vs MenACWY-TT in Healthy Toddlers
NCT01994629Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2013
- Primary completion
- Apr 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen in meningococcal disease (2 arms), sponsored by Novartis. Primary endpoint: Number of Subjects With at Least One Severe Solicited Adverse Event. Started Nov 2013; status: completed.
02
Drugs
neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT01994629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01994629.